Sulfadiazine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Sulfadiazine: From Toxoplasmosis to Pneumocystosis
One-Sentence Summary
Sulfadiazine, typically used in combination with pyrimethamine as a standard treatment for toxoplasmosis, is predicted by the TxGNN model to have potential activity against pneumocystosis (Pneumocystis pneumonia). This direction is currently supported by 20 publications (mostly historical reviews and case reports) and no registered clinical trials, placing it firmly at the hypothesis-generating stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack’s regulatory data; historically used with pyrimethamine as the standard combination for toxoplasmosis (per literature cited in the rationale) |
| Predicted New Indication | Pneumocystosis (Pneumocystis pneumonia) |
| TxGNN Prediction Score | 99.39% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is flagged as a data gap in the structured record. Based on the mechanistic rationale accompanying this prediction, sulfadiazine is a folate synthesis inhibitor (dihydropteroate synthase inhibition), and its combination with pyrimethamine (which blocks a second step in folate metabolism) is the established standard regimen for toxoplasmosis, an opportunistic infection common in immunocompromised (e.g. HIV/AIDS) patients.
Pneumocystosis (caused by the fungus-like organism Pneumocystis jirovecii) is treated with a related but distinct agent — trimethoprim-sulfamethoxazole (TMP-SMX), not sulfadiazine. The two conditions frequently co-occur in the same AIDS patient population, which likely explains why they appear together repeatedly in the literature and why the TxGNN graph model has linked them. However, this co-occurrence largely reflects shared clinical context (patients being treated for both infections simultaneously) rather than direct pharmacological evidence that sulfadiazine itself is effective against P. jirovecii.
The theoretical link is therefore indirect: sulfadiazine and sulfamethoxazole belong to the same sulfonamide class and share a folate-pathway mechanism, which provides a plausible but unproven rationale. This should currently be regarded as a research hypothesis rather than an established therapeutic signal.
Clinical Trial Evidence
Currently no related clinical trials registered for pneumocystosis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2645082 | 1989 | Cohort/Case series | Clinical Pharmacy | Pyrimethamine-sulfadiazine used for treating PCP and toxoplasmosis in AIDS patients |
| 5315969 | 1971 | Case report | Annals of Internal Medicine | PCP treated with pyrimethamine and sulfadiazine |
| 2969023 | 1988 | Review | The Journal of Infectious Diseases | Overview of PCP therapy and prophylaxis options |
| 12645193 | 2002 | Case report | J Formosan Medical Association | Concurrent Toxoplasma brain abscess and PCP in an AIDS patient; treated with clindamycin and sulfadiazine |
| 3914245 | 1985 | Review | Archives Françaises de Pédiatrie | Paediatric Pneumocystis carinii infections; TMP as mainstay treatment |
| 3897099 | 1985 | Review | Der Internist | General review of Pneumocystis carinii pneumonia |
| 9097375 | 1997 | Review | Seminars in Respiratory Infections | Toxoplasma pneumonia in immunocompromised hosts |
| 7355683 | 1980 | Review | American Family Physician | Antiparasitic drugs of choice; TMP-SMX cited for PCP, pyrimethamine-sulfadiazine for resistant malaria |
| 4580723 | 1973 | Review | Transplantation Proceedings | Diagnosis and treatment of pneumocystosis and toxoplasmosis in immunosuppressed hosts |
| 2011633 | 1991 | Review | Primary Care | PCP and CNS toxoplasmosis as major AIDS-associated parasitic diseases |
UK Market Information
Sulfadiazine currently holds no MHRA marketing authorisations in the UK (0 licences on record); market status is Not marketed. No dosage forms or approved indication text are available in this evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications, and DDI data are marked as a Blocking data gap in this evidence pack — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link between sulfadiazine and pneumocystosis is indirect — it relies on structural similarity to sulfamethoxazole (the actual active component in the established PCP treatment, TMP-SMX) and on co-occurrence in AIDS patients treated for both toxoplasmosis and PCP simultaneously, rather than direct pharmacological evidence. No clinical trials have been registered, the supporting literature is historical (predominantly 1970s–1990s reviews and case reports), and a Blocking data gap (missing MHRA warnings/contraindications) currently prevents any safety pre-assessment. Sulfadiazine is also not currently marketed in the UK.
To proceed, the following is needed:
- MHRA-authorised SmPC/PIL data (or equivalent) to resolve the Blocking safety data gap and enable an S1 safety pre-assessment
- Confirmation of detailed mechanism of action from DrugBank or primary pharmacology sources
- Contemporary controlled or observational studies specifically evaluating sulfadiazine (as distinct from sulfamethoxazole/TMP-SMX) against Pneumocystis jirovecii
- Clarification of a UK supply/import pathway, given the drug currently holds no UK marketing authorisation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.